278 related articles for article (PubMed ID: 29213088)
21. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.
Papillon-Cavanagh S; Lu C; Gayden T; Mikael LG; Bechet D; Karamboulas C; Ailles L; Karamchandani J; Marchione DM; Garcia BA; Weinreb I; Goldstein D; Lewis PW; Dancu OM; Dhaliwal S; Stecho W; Howlett CJ; Mymryk JS; Barrett JW; Nichols AC; Allis CD; Majewski J; Jabado N
Nat Genet; 2017 Feb; 49(2):180-185. PubMed ID: 28067913
[TBL] [Abstract][Full Text] [Related]
22. NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
Brennan K; Zheng H; Fahrner JA; Shin JH; Gentles AJ; Schaefer B; Sunwoo JB; Bernstein JA; Gevaert O
Hum Mol Genet; 2022 Jul; 31(13):2164-2184. PubMed ID: 35094088
[TBL] [Abstract][Full Text] [Related]
23. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor.
Seo JS; Kim A; Shin JY; Kim YT
Sci Rep; 2018 Oct; 8(1):14576. PubMed ID: 30275546
[TBL] [Abstract][Full Text] [Related]
25. MLPA analysis in 30 Sotos syndrome patients revealed one total NSD1 deletion and two partial deletions not previously reported.
Fagali C; Kok F; Nicola P; Kim C; Bertola D; Albano L; Koiffmann CP
Eur J Med Genet; 2009; 52(5):333-6. PubMed ID: 19596467
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis of Sotos syndrome.
Niikawa N
Horm Res; 2004; 62 Suppl 3():60-5. PubMed ID: 15539801
[TBL] [Abstract][Full Text] [Related]
27. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
28. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
29. Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1.
Kudithipudi S; Lungu C; Rathert P; Happel N; Jeltsch A
Chem Biol; 2014 Feb; 21(2):226-37. PubMed ID: 24412544
[TBL] [Abstract][Full Text] [Related]
30. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
31. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
32. Leukocyte cDNA analysis of NSD1 derived from confirmed Sotos syndrome patients.
Duno M; Skovby F; Schwartz M
Ann Hum Genet; 2007 Nov; 71(Pt 6):713-8. PubMed ID: 17561922
[TBL] [Abstract][Full Text] [Related]
33. Role of NSD1 in H2O2-induced GSTM3 suppression.
Chu G; Li Y; Dong X; Liu J; Zhao Y
Cell Signal; 2014 Dec; 26(12):2757-64. PubMed ID: 25193115
[TBL] [Abstract][Full Text] [Related]
34. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
35. Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Szaumkessel M; Wojciechowska S; Janiszewska J; Zemke N; Byzia E; Kiwerska K; Kostrzewska-Poczekaj M; Ustaszewski A; Jarmuz-Szymczak M; Grenman R; Wierzbicka M; Bartochowska A; Szyfter K; Giefing M
Tumour Biol; 2017 Mar; 39(3):1010428317691427. PubMed ID: 28345455
[TBL] [Abstract][Full Text] [Related]
36. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.
Wang GG; Cai L; Pasillas MP; Kamps MP
Nat Cell Biol; 2007 Jul; 9(7):804-12. PubMed ID: 17589499
[TBL] [Abstract][Full Text] [Related]
37. Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.
Rieke DT; Ochsenreither S; Klinghammer K; Seiwert TY; Klauschen F; Tinhofer I; Keilholz U
Oncotarget; 2016 Nov; 7(46):75379-75393. PubMed ID: 27683114
[TBL] [Abstract][Full Text] [Related]
38. NSD1 mutations in Sotos syndrome.
Faravelli F
Am J Med Genet C Semin Med Genet; 2005 Aug; 137C(1):24-31. PubMed ID: 16010675
[TBL] [Abstract][Full Text] [Related]
39. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
[TBL] [Abstract][Full Text] [Related]
40. Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma.
Xia L; Lin H; Cao H; Lian J
BMC Cancer; 2024 May; 24(1):561. PubMed ID: 38711034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
